Caleosin-based nanoscale oil bodies for targeted delivery of hydrophobic anticancer drugs
Source abstract
Abstract
Nanoscale artificial oil bodies (NOBs) could be assembled from plant oil, phospholipids (PLs), and oleosin (Ole) as previously reported. NOBs have a lipid-based structure that contains a central oil space enclosed by a monolayer of Ole-bound PLs. As an oil structural protein, Ole functions to maintain the integrity of NOBs. Like Ole, caleosin (Cal) is a plant oil-associated protein. In this study, we investigated the feasibility of NOBs assembled by Cal for targeted delivery of drugs. Cal was first fused with anti-HER2/neu affibody (ZH2), and the resulting fusion gene (Cal–ZH2) was then expressed in Escherichia coli. Consequently, NOBs assembled with the fusion protein were selectively internalized by HER2/neu-positive tumor cells. The internalization efficiency could reach as high as 90%. Furthermore, a hydrophobic anticancer drug, Camptothecin (CPT), was encapsulated into Cal-based NOBs. These CPT-loaded NOBs had a size around 200 nm and were resistant to hemolysis. Release of CPT from NOBs at the non-permissive condition followed a sustained and prolonged profile. After administration of the CPT formulation, Cal–ZH2-displayed NOBs exhibited a strong antitumor activity toward HER2/neu-positive cells both in vitro and in vivo. The result indicates the potential of Cal-based NOBs for targeted delivery of hydrophobic drugs.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Porphyrin and Phthalocyanine Chemistry · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (36)
Show source-provided references
1. Andresen TL, Jensenb SS, Jørgensen K (2005) Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44:68–9710.1016/j.plipres.2004.12.001 ↗
2. Barreiro-Iglesias R, Bromberg L, Temchenko M, Hatton TA, Concheiro A, Alvarez-Lorenzo C (2004) Solubilization and stabilization of camptothecin in micellar solutions of pluronic-g-poly(acrylic acid) copolymers. J Control Release 97:537–54910.1016/j.jconrel.2004.04.007 ↗
3. Chen JC, Tsai CC, Tzen JTC (1999) Cloning and secondary structure analysis of caleosin, a unique calcium-binding protein in oil bodies of plant seeds. Plant Cell Physiol 40:1079–108610.1093/oxfordjournals.pcp.a029490 ↗
4. Chen MC, Chyan CL, Lee TT, Huang SH, Tzen JTC (2004) Constitution of stable artificial oil bodies with triacylglycerol, phospholipid, and caleosin. J Agric Food Chem 52:3982–398710.1021/jf035533g ↗
5. Chiang CJ, Chen CJ, Chang CH, Chao YP (2010) Selective delivery of cargo entities to tumor cells by nanoscale artificial oil bodies. J Agric Food Chem 58:11695–1170210.1021/jf102944c ↗
6. Chiang CJ, Lin LJ, Lin CC, Chang CH, Chao YP (2011) Selective internalization of self-assembled artificial oil bodies by HER2/neu-positive cells. Nanotechnology 22:01510210.1088/0957-4484/22/1/015102 ↗
7. Cho K, Wang X, Nie S, Chen Z, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310–131610.1158/1078-0432.CCR-07-1441 ↗
8. Chuang RLC, Chen JCF, Chu J, Tzen JTC (1996) Characterization of seed oil bodies and their surface oleosin isoforms from rice embryos. J Biochem 120:74–8110.1093/oxfordjournals.jbchem.a021396 ↗
9. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505–51610.1038/nrm1962 ↗
10. Elbayoumi TA, Pabba S, Roby A, Torchilin VP (2007) Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res 17:1–1410.1080/08982100601186474 ↗
11. Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3:16–2010.1021/nn900002m ↗
12. Fernandez AM, Van derpoorten K, Dasnois L, Lebtahi K, Dubois V, Lobl TJ, Gangwar S, Oliyai C, Lewis ER, Shochat D et al (2001) N-Succinyl-(β-alanyl-l-leucyl-l-alanyl-l-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity. J Med Chem 44:3750–375310.1021/jm0108754 ↗
13. Ferrari M (2005) Nanotechnology: opportunities and challenges. Nat Rev Cancer 5:161–17110.1038/nrc1566 ↗
14. Frandsen GI, Mundy J, Tzen JTC (2001) Oil bodies and their associated proteins oleosin and caleosin. Physiol Plant 112:301–30710.1034/j.1399-3054.2001.1120301.x ↗
15. Garcia-Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the Camptothecins. Clin Cancer Res 8:641–661
16. Huang AH (1996) Oleosins and oil bodies in seeds and other organs. Plant Physiol 110:1055–106110.1104/pp.110.4.1055 ↗
17. Hung MC, Lau YK (1999) Basic science of HER2/neu: a review. Semin Oncol 26:51–59
18. Lacey DJ, Wellner N, Beaudoin F, Napier JA, Shewry PR (1998) Secondary structure of oleosins in oil bodies isolated from seeds of safflower (Carthamus tinctorius L.) and sunflower (Helianthus annuus L.). Biochem J 334:469–47710.1042/bj3340469 ↗
19. Lee HK, Lee HY, Jeon JM (2007) Codeposition of micro- and nano-sized SiC particles in the nickel matrix composite coatings obtained by electroplating. Surf Coat Tech 201:4711–471710.1016/j.surfcoat.2006.10.004 ↗
20. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2000) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–3610.1016/S0169-409X(00)00129-0 ↗
21. Liu TH, Chyan CL, Li FY, Tzen JTC (2009) Stability of artificial oil bodies constituted with recombinant caleosins. J Agric Food Chem 57:2308–231310.1021/jf803566w ↗
22. Miller JH (1972) Experiments in molecular genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor
23. Napier JA, Stobart AK, Shewry PR (1996) The structure and biogenesis of plant oil bodies: the role of the ER membrane and the oleosin class of proteins. Plant Mol Biol 31:945–95610.1007/BF00040714 ↗
24. Orlova A, Magnusson M, Eriksson TLJ, Nilsson M, Larsson B, Hoiden-Guthenberg I, Widstrom C, Carlsson J, Tolmachev V, Stahl S et al (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66:4339–434810.1158/0008-5472.CAN-05-3521 ↗
25. Shao RG, Cao CX, Shimizu T, O’Connor PM, Kohn KW, Pommier Y (1997) Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-O1) in human cancer cell lines, possibly Influenced by p53 function. Cancer Res 57:4029–4035
26. Shmeedaa H, Tzemacha D, Maka L, Gabizon A (2009) Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. J Control Release 136:155–16010.1016/j.jconrel.2009.02.002 ↗
27. Soepenberg O, Sparreboom A, Verweij J (2003) The Alkaloids: clinical studies of Camptothecin and derivatives. Chem Biol 60:1–50
28. Steffen AC, Orlova A, Wikman M, Nilsson FY, Ståhl S, Adams GP, Tolmachev V, Carlsson J (2006) Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imag 33:631–63810.1007/s00259-005-0012-3 ↗
29. Sugarman SM, Zou YY, Wasan K, Poirot K, Kumi R, Reddy S, Perez-Soler R (1996) Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies. Cancer Chemother Pharmacol 37:531–53810.1007/s002800050425 ↗
30. Suthiwangcharoen N, Li T, Li K, Thompson P, You S, Wang Q (2011) M13 bacteriophage-polymer nanoassemblies as drug delivery vehicles. Nano Res 4:483–49310.1007/s12274-011-0104-2 ↗
31. Torchilin VP (2005) Lipid-core micelles for targeted drug delivery. Curr Drug Deliv 2:319–32710.2174/156720105774370221 ↗
32. Torchilin VP (2007) Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 24:1–1610.1007/s11095-006-9132-0 ↗
33. Tzen JTC, Lie GC, Huang AH (1992) Characterization of the charged components and their topology on the surface of plant seed oil bodies. J Biol Chem 267:15626–1563410.1016/S0021-9258(19)49582-3 ↗
34. Venditto VJ, Simaneck EE (2010) Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharm 7:307–34910.1021/mp900243b ↗
35. Wenkai T, Wang L, D’Souza MJ (2003) Evaluation of PLGA microspheres as delivery system for antitumor agent-camptothecin. Drug Dev Ind Pharm 29:745–75610.1081/DDC-120021774 ↗
36. Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, Alexis F, Langer R, Farokhzad OC (2008) Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 8:1696–170210.1021/nn800275r ↗